BDRX

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals PLC

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BDRX

1 2 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/22	21 : 30	GlobeNewswire Inc.	Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2024/05/21	21 : 30	GlobeNewswire Inc.	Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2024/05/15	16 : 57	GlobeNewswire Inc.	Posting of Annual Report & Notice of AGM - Total Voting Rights	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2024/05/01	00 : 51	GlobeNewswire Inc.	Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2024/04/26	21 : 30	GlobeNewswire Inc.	Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2024/04/19	21 : 00	GlobeNewswire Inc.	Preliminary Results for the Year Ended 31 December 2023	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2024/02/23	22 : 30	GlobeNewswire Inc.	Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2024/02/13	22 : 15	AllPennyStocks.com	Biotech Shares Bid Up Premarket Following 9.9% Institutional Stake Disclosure	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2024/02/08	22 : 30	GlobeNewswire Inc.	Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2024/02/07	22 : 30	GlobeNewswire Inc.	Biodexa Announces Allowance of U.S. Patent Covering Tolimidone	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2024/01/22	22 : 30	GlobeNewswire Inc.	Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/12/29	18 : 05	GlobeNewswire Inc.	Biodexa Appoints Ann Merchant to the Board of Directors	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/12/22	06 : 00	GlobeNewswire Inc.	Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/12/19	22 : 42	GlobeNewswire Inc.	Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/11/27	23 : 00	GlobeNewswire Inc.	Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/10/03	21 : 30	GlobeNewswire Inc.	Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/09/30	05 : 30	GlobeNewswire Inc.	Interim results for the six months ended 30 June 2023	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/09/21	21 : 30	GlobeNewswire Inc.	Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/07/28	21 : 00	GlobeNewswire Inc.	Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/07/24	20 : 30	GlobeNewswire Inc.	Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/07/10	21 : 00	GlobeNewswire Inc.	Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/07/07	05 : 30	GlobeNewswire Inc.	Results of Appeal of Delisting Determination	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/07/06	21 : 15	GlobeNewswire Inc.	Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/06/23	05 : 15	GlobeNewswire Inc.	ADR Ratio Change	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/06/20	21 : 00	GlobeNewswire Inc.	Appeal of Delisting Determination	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/06/16	05 : 05	GlobeNewswire Inc.	Receipt of NASDAQ Delisting Determination Plans to Appeal	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/06/14	21 : 30	GlobeNewswire Inc.	Results of Annual General Meeting and General Meeting	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/05/27	05 : 05	GlobeNewswire Inc.	Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/05/24	21 : 40	GlobeNewswire Inc.	Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC
2023/05/23	05 : 15	GlobeNewswire Inc.	Posting of Annual Report & Notice of AGM	NASDAQ:BDRX	Biodexa Pharmaceuticals PLC